Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

This trial will investigate the safety, tolerability and pharmacokinetics of single escalating doses of AZD 2836 [A 831; Arrow Therapeutics], a small molecule antiviral inhibitor of hepatitis C, in volunteers.

Next Previous
Trial Profile

This trial will investigate the safety, tolerability and pharmacokinetics of single escalating doses of AZD 2836 [A 831; Arrow Therapeutics], a small molecule antiviral inhibitor of hepatitis C, in volunteers.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 2836 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Arrow Therapeutics

Most Recent Events

  • 29 Nov 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top